First Patients Enrolled in IMPRoVED-AF Study Using vMap, a Non-Invasive ECG-Based Tool Designed to Guide More Effective AF Ablation
SAN DIEGO, July 09, 2025--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming standard ECG data into actionable insights that guide arrhythmia care, today announced that Baptist Health Lexington has enrolled the first patients in the IMPRoVED-AF clinical study. Baptist Health Lexington, a 434-bed acute care hospital, is a long-time leader in innovative approaches to treat heart disease and related conditions.
IMPRoVED-AF is a prospective, randomized, controlled, international, multi-center study designed to rigorously compare clinical outcomes in patients undergoing pulmonary vein isolation (PVI) alone versus PVI and additional driver ablation guided by vMap®, the only FDA-cleared non-invasive arrhythmia analysis technology designed to improve, enhance, and accelerate ablation procedures, utilizing data from a standard 12-lead ECG. The study aims to demonstrate the comparative clinical benefit of using vMap to identify and ablate non-pulmonary vein electrical drivers, when used alongside standard-of-care ablation techniques, including advanced technologies such as pulsed field ablation (PFA), in patients with persistent and recurrent atrial fibrillation (AF).
"Enrolling the first patient in the IMPRoVED-AF study marks an important milestone in our ongoing efforts at Baptist Health to further advance care for our patients suffering from cardiac arrhythmias," said Dr. Gery Tomassoni, Principal Investigator and cardiac electrophysiologist at Baptist Health Lexington. "For patients with persistent and recurrent AF, treatment has often been ineffective due to the inability to identify the source of the arrhythmia. Using vMap to determine a targeted ablation strategy beyond the pulmonary veins provides an opportunity to target drivers that were previously undetectable. That means better care and more effective, lasting results for patients."
With growing pressure to improve outcomes and reduce re-do procedures, physicians and hospitals are seeking non-invasive tools that can improve targeting while maintaining necessary workflow efficiencies. vMap is designed to address this need by delivering rapid analysis and insights from a standard 12-lead ECG.
"The IMPRoVED-AF study is an important validation of the meaningful impact vMap is already delivering in the EP lab," said Rob Krummen, CEO of Vektor Medical. "This isn't about incremental improvement; it's a leap forward in how we identify and treat complex arrhythmias. vMap is uncovering drivers that often go undetected, helping physicians deliver more effective and durable outcomes. This study is a critical part of our strategy to build the clinical evidence that drives confident adoption, supports value in health systems, and positions vMap as the new standard in arrhythmia care."
The IMPRoVED-AF study, managed by Veranex, a global leader in clinical research, will enroll up to 384 patients with persistent and recurrent AF at approximately 20 electrophysiology centers across the United States and Europe. The primary endpoint of the study is freedom from AF at 12 months.
To learn more about the IMPRoVED-AF study, explore vMap technology, or request a clinical or strategic briefing, visit www.vektormedical.com and connect with us on LinkedIn and X.
About vMap®
vMap is the only FDA-cleared, non-invasive solution that transforms data from a standard 12-lead ECG into actionable insights to guide arrhythmia care. The technology, developed with AI, localizes arrhythmia source locations across all four chambers of the heart — including both focal and fibrillation-type arrhythmias. vMap is used by electrophysiologists during triage, procedural planning, and ablation to help identify and target arrhythmia drivers more quickly and with greater confidence. Backed by growing clinical evidence, use of vMap has been associated with improved outcomes, reduced procedure time, and streamlined workflow across the arrhythmia care continuum.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is working to improve outcomes, enhance efficiencies, and accelerate access to effective treatment strategies. To learn more, visit www.vektormedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250709915203/en/
Contacts
Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@levitatenow.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple locations simultaneously with a high level of expertise RadNet has connected more than 300 MR, CT, PET/CT, and Ultrasound systems with TechLive™, delivering operational efficiency and increased access to advanced procedures LOS ANGELES and SOMERVILLE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and global leader in AI-powered health informatics, announced today that it has received FDA 510(k) clearance for TechLive™ - a remote scanning solution enabling centralized operation and supervision of MR, CT, PET/CT, and Ultrasound procedures. Amidst tech labor shortages and inflationary wage pressure, TechLive™ empowers technologists to scan for multiple locations, enables improved operational efficiency, extends center operating hours, and enhances access to complex procedures. More than 300 of RadNet's MR, CT, PET/CT, and Ultrasound systems are now connected with DeepHealth's TechLive™ solution, resulting in increased patient throughput and improved quality through remotely matching expert staff with complex modalities in real-time. Over the past decade, radiology workloads have steadily increased, while the number of qualified technologists have not grown proportionally. In a pilot deployment at 64 locations inside of RadNet's New York area facilities, TechLive™ significantly contributed to a 42% decrease in MRI room closure hours during the second quarter of 2025 as compared with the same period in 2024, allowing more patients to receive timely scans. Additionally, as a result of the remote expert involvement during the same pilot deployment, TechLive™ contributed to an increase in complex procedures. Furthermore, in extending remote scanning capabilities to Ultrasound, TechLive™ is enabling experienced senior sonographers and physicians to remotely guide technologists on-site through complex cases in a modality that is heavily dependent upon real-time, operator expertise. "TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries." About DeepHealthDeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. About RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit DeepHealth ContactAndra AxenteDirector of Communications+ RadNet, Inc. ContactMark StolperExecutive Vice President and Chief Financial Officer310-445-2800 Forward-Looking Statements This communication contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'possible,' 'predict,' 'project,' 'seek, 'should,' 'target,' 'will' or 'would,' the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the streamlining of delivery and deployment across healthcare facilities, and TechLive creating a foundation for more efficient, financially sustainable and high-quality patient care across the broadest set of imaging modalities, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet's control. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of RadNet's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's control. RadNet's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet nor its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet's business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the Securities and Exchange Commission (the 'SEC'), including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC. Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.
New York Post
6 hours ago
- New York Post
FDA pulls popular ice cream from shelves after packaging mix up: ‘Serious allergic reaction'
Ice cream lovers may have more than a meltdown. Friendly's Ice Cream has recalled one of its most popular flavors after a packaging mix up sparking an allergy risk warning from the Food and Drug Administration, which who said it could cause 'a serious or life-threatening allergic reaction.' DFA Dairy Brands, LLC, voluntarily pulled 324 cartons of its 48-fluid-ounce Friendly's Cookies & Cream ice cream from stores after they were packaged in Vanilla Bean containers but topped with Cookies & Cream lids, the FDA said. 3 Friendly's Ice Cream their Cookies & Cream ice cream from stores across the nation. Paul Weaver/SOPA Images / Shutterstock The Vanilla Bean flavor does not contain soy or wheat, which are present in Cookies & Cream. Therefore, the Vanilla Bean cartons don't list those ingredients, according to the FDA. 'For many people, a reaction to soy or wheat usually means abdominal pain, but you could get a rash, or less commonly, asthma-like symptoms,' said Dr. Joseph Raduazzo, an internal medicine specialist in Massachusetts. 3 Federal officials are warning that the mislabeling could have deadly consequences for allergy sufferers. friendlys 'For people with a severe allergy to soy or wheat, the reaction could be life-threatening, similar to when people with peanut allergies come into contact with the nut.' No illnesses or adverse reactions have been reported due to the mispackaging, according to the FDA website. The recalled ice cream was distributed through a single distribution center, UNFI, to retail stores in Maryland, Virginia and Pennsylvania, the agency said. 3 The recall was issued due to the Food and Drug Administration saying in what was a package mix-up that the 324 cartons of ice cream posed an allergy risk that can cause 'a serious or life-threatening allergic reaction.' REUTERS No other Friendly's products were included, a recorded message on a Friendly's consumer hotline said. Last month, Florida-based Rich's Ice Cream recalled over 100,000 ice cream bars in 23 states – including New York and Pennsylvania – due to listeria concerns. The voluntary removal from the market was one of the largest ice cream recalls in recent history.
Buzz Feed
7 hours ago
- Buzz Feed
Kim Kardashian Stem Cell Treatment Post Draws Ire
Kim Kardashian is under fire after promoting an expensive stem cell treatment. In an Aug. 8 Instagram post, Kim talked about traveling to Mexico to receive stem cell therapy to treat "debilitating pain" caused by a shoulder injury from lifting weights two years ago. According to her, she'd "tried everything to find relief" before visiting Dr. Adeel Khan at Eterna Health and achieving "immediate" results. Kim said, "I regained full range of motion, and my shoulder has felt completely normal ever since." The positive experience led her to return to Dr. Khan "to address chronic back pain that I have been suffering with for years." Kim shared, "The Muse stem cell treatment was a game-changer once again. I experienced relief right away, and the unbearable pain is finally gone." She highly recommended the treatment for anyone struggling with back pain, writing, "It's transformed my life when I thought my body was breaking down." Except, for many people, stem cell treatment is wildly unaffordable. According to Global Stem Cell Therapy, costs in Mexico can be anywhere between $4,000 and $15,000. On top of that, many stem cell treatments are not FDA-approved, including those for shoulder and back pain. That said, many people weren't feeling Kim's post. This person straight-up told her, "Kimmy we're poor." Another commented, "Kim, there's people that are dying." Others wished they had that luxury... ...And accepted they'll have to live with their pain forever because they aren't rich. Another person sarcastically said, "Sounds super affordable." As others pointed out how wildly out-of-touch Kim's post was in the current economy. You can see more comments below, and then let me know what you think in the comments.
